Work

Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system

Year: 2025

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2025.2593350

Authors: C. Balmaceda, N. Armijo, M. Espinoza

Institutions: University of Hong Kong, Bocconi University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4416529385

FWCI:

Cites: 22

Cited by:

Related to: